Pro-arrhythmic potential of proton-pump inhibitors.
No abstract available
COI Statement
Competing interests: P.E.L. received a grant from Roche Italia S.p.A in 2018. The other authors declare no competing interests.
References:
Xie, Y. et al. Estimates of all cause mortality and cause specific mortality associated with proton pump inhibitors among US veterans: cohort study. BMJ 365, l1580 (2019).
Eroglu, T. E., Coronel, R. & Gislason, G. H. Use of proton pump inhibitors is associated with increased risk of out-of-hospital cardiac arrest in the general population: a nested case-control study. Eur. Heart J. Cardiovasc. Pharmacother. 10, 413–419 (2024).
Famularo, G., Gasbarrone, L. & Minisola, G. Hypomagnesemia and proton-pump inhibitors. Expert Opin. Drug Saf 12, 709–716 (2013).
Chrysant, S. G. Proton pump inhibitor-induced hypomagnesemia complicated with serious cardiac arrhythmias. Expert Rev. Cardiovasc. Ther. 17, 345–351 (2019).
Lazzerini, P. E. et al. Proton pump inhibitors and serum magnesium levels in patients with torsades de pointes. Front. Pharmacol. 9, 363 (2018).